Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.52 |
| ▸ | ACP1 | P24666 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436700 | 0.88 | TACR3 (0.52) | L3MBTL1TACR3ACP1RAB9AEGFR | |
| SCHEMBL30691740 | 0.83 | HDAC8 (0.60) | TDP1HDAC1HDAC8HDAC6L3MBTL1 | |
| SCHEMBL8557712 | 0.83 | HDAC1 (0.54) | HDAC1HDAC8HDAC6L3MBTL1TACR3 | |
| SCHEMBL6689330 | 0.81 | LMNA (0.55) | HDAC1HDAC8HDAC6L3MBTL1TACR3 | |
| SCHEMBL6814420 | 0.81 | NCF1 (0.54) | HDAC1L3MBTL1TACR3ACP1RAB9A | |
| SCHEMBL5436695 | 0.81 | POLB (0.55) | TDP1L3MBTL1ACP1RAB9ANPC1 | |
| SCHEMBL413427 | 0.80 | TDP1 (0.56) | TDP1L3MBTL1ACP1SMN1; SMN2P2RX7 | |
| SCHEMBL11037476 | 0.79 | GAA (0.59) | L3MBTL1TACR3ACP1RAB9AEGFR | |
| SCHEMBL10787691 | 0.79 | RAB9A (0.55) | TACR3ACP1RAB9AEGFRTP53 | |
| SCHEMBL11510637 | 0.78 | HDAC1 (0.59) | HDAC1HDAC8HDAC6L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039158-A | Preparation method of aromatic amine compound | 浙江工业大学 | 2024-11-29 | — | — | CN | disclosed |
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| EP-2925723-A1 | ZINC HALIDE MEDIATED CYCLIZATION PROCESS LEADING TO TRICYCLIC INDOLES | GE Healthcare Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083163-A1 | ZINC HALIDE MEDIATED CYCLIZATION PROCESS LEADING TO TRICYCLIC INDOLES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1438290-B1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | KINNICK MICHAEL DEAN (US) | 2005-02-03 | — | — | US | disclosed |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | KINNICK MICHAEL DEAN (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1438290-A1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| WO-2003016277-A1 | CYCLOHEPT`B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| CN-1240210-A | Substituted tricyclic compound | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | PTGIS, PLA2G4A, PLA2G4B | TDP1 2766/4885HDAC1 3437/4885HDAC8 4055/4885 |
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | IDO1, IDO2, TPH2 | TDP1 3208/4885HDAC1 111/4885HDAC8 451/4885 |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | SPTSSB, CPT1A, TPH2 | TDP1 2538/4885HDAC1 2499/4885HDAC8 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.